Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled studyYameng Sun, Hong You, Yueyong Zhu et al.|Hepatology|2025Cited by 10
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 studyRui Hua, Junqi Niu, Fei Kong et al.|Journal of Viral Hepatitis|2022Cited by 7
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in ChinaRui Hua, Junqi Niu, Fei Kong et al.|Infectious Diseases and Therapy|2023Cited by 6
A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infectionRui Hua, Junqi Niu, Fei Kong et al.|Journal of Hepatology|2020Cited by 1
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in ChinaRui Hua, Junqi Niu, Fei Kong et al.|Research Square|2023Cited by 1